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Caveolin-1 is Associated with 
Tumor Progression and Confers 
a Multi-Modality Resistance 
Phenotype in Pancreatic Cancer
Moumita Chatterjee1, Edgar Ben-Josef2, Dafydd G. Thomas3, Meredith A. Morgan3, 
Mark M. Zalupski3, Gazala Khan4, Charles Andrew Robinson1, Kent A. Griffith3, 
Ching-Shih Chen1, Thomas Ludwig1, Tanios Bekaii-Saab1, Arnab Chakravarti1 & 
Terence M. Williams1
Caveolin-1 (Cav-1) is a 21 kDa protein enriched in caveolae, and has been implicated in oncogenic 
cell transformation, tumorigenesis, and metastasis. We explored roles for Cav-1 in pancreatic 
cancer (PC) prognostication, tumor progression, resistance to therapy, and whether targeted 
downregulation could lead to therapeutic sensitization. Cav-1 expression was assessed in cell 
lines, mouse models, and patient samples, and knocked down in order to compare changes in 
proliferation, invasion, migration, response to chemotherapy and radiation, and tumor growth. 
We found Cav-1 is overexpressed in human PC cell lines, mouse models, and human pancreatic 
tumors, and is associated with worse tumor grade and clinical outcomes. In PC cell lines, disruption/
depletion of caveolae/Cav-1 reduces proliferation, colony formation, and invasion. Radiation and 
chemotherapy up-regulate Cav-1 expression, while Cav-1 depletion induces both chemosensitization 
and radiosensitization through altered apoptotic and DNA repair signaling. In vivo, Cav-1 depletion 
significantly attenuates tumor initiation and growth. Finally, Cav-1 depletion leads to altered JAK/
STAT, JNK, and Src signaling in PC cells. Together, higher Cav-1 expression is correlated with worse 
outcomes, is essential for tumor growth and invasion (both in vitro and in vivo), is responsible for 
promoting resistance to therapies, and may serve as a prognostic/predictive biomarker and target in 
PC.
Pancreatic carcinoma remains one of the most lethal cancers with a high mortality rate within the first 
year of diagnosis and a dismal 6% five year survival rate1. An estimated 46,420 new cases of pancreatic 
cancer will be diagnosed in 2014 in the U.S., of which approximately 39,590 people are estimated to die 
from this deadly disease1. Despite significant advancements in therapy, late presentation and rapid pro-
gression make it a difficult disease to treat and cure. The fibrotic nature of the stroma surrounding the 
tumor perhaps presents an appreciable barrier for therapies2,3, but the factors responsible for the aggres-
siveness of pancreatic cancer are still under investigation. This highlights the need for identification of 
useful biomarkers that would correlate pathological advancement of the disease and prognosis, and help 
select patients who would benefit most from multimodality treatment.
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Caveolin-1 (Cav-1) is a 21 kDa protein found in “cave-like” invaginations of the cell membrane 
termed caveolae. Cav-1 is a major structural component of these 50-100 nm sized organelles, and is a 
requirement for their formation, as genetic ablation of Cav-1 renders many cell types devoid of caveolae4. 
Cav-1/caveolae are involved in various cellular pathways including, but not limited to, endocytosis, lipid 
homeostasis, and signal transduction5–7. Cav-1 has been implicated in the pathogenesis of oncogenic 
cell transformation and metastasis and has seemingly opposite roles of being either a tumor suppressor 
or an oncogene depending on the cancer type (breast or prostate) and tissue of interest (e.g. tumor or 
stroma)8–11.
In pancreatic cancer, Cav-1 is upregulated and has been correlated with poor prognosis or aggressive-
ness of the tumor8,12. Downregulation of caveolin-1 has been previously shown to sensitize cancer cells 
to ionizing radiation13. It has also been shown to mediate radioresistance in pancreatic cancer (PC) cells 
grown in three-dimensional culture14. Thus, Cav-1 expression in pancreatic cancer may be important for 
the prognosis of this disease.
In addition to surgical resection, current therapeutic strategies to treat pancreatic cancer include 
radiation and chemotherapeutics like gemcitabine, 5-fluorouracil, oxaliplatin, nab-paclitaxel, and irinote-
can15,16. The identification of reliable biomarkers is needed to both prognosticate and potentially predict 
effective therapy for patients according to their tumor’s molecular profile. Here, we show that Cav-1 
levels in pancreatic cancer could potentially serve as a prognostic biomarker. We establish roles for 
Cav-1 in both apoptotic and DNA damage response signaling in response to therapeutic stress. Finally, 
we demonstrate that targeting Cav-1 through genetic down-regulation in human pancreatic cancer cells 
can attenuate tumor growth and sensitize tumor cells to chemotherapeutics and radiation.
Results
Caveolin-1 is Overexpressed in Pancreatic Cancer In Vitro and In Vivo, is Associated with 
Increasing Tumor Grade, CA19-9 Levels, and Worse Clinical Outcomes. Caveolin-1 has been 
implicated to have both pro-tumorigenic and tumor suppressive roles, depending on the tissue type and 
histopathology of tumors5,17. In pancreatic cancer, the role of Cav-1 is not well-defined. We determined 
Cav-1 expression in a panel of PC cell lines as well as normal human pancreatic ductal epithelium 
(HPDE) cells and HEK-293 kidney epithelial cells. Cav-1 expression was low in these normal cell lines, 
but highly up-regulated in 5 of 7 PC cell lines (Fig. 1A). Likewise, Cav-1 expression was virtually absent 
in normal human pancreatic epithelium, but expressed in neighboring adipose and endothelial cells, as 
expected (Fig.  1B). However, Cav-1 was clearly up-regulated in subcutaneous xenograft tumor tissue 
derived from MIAPaCa-2 cells, patient-derived xenografts, and tumors from a well-characterized mouse 
model of pancreatic cancer bearing p53 (p53LSL-R270H) and KRAS (KRASLSL-G12D) mutations expressed in 
pancreatic epithelium with the Pdx1-cre transgene (“KPC mouse”) (Fig. 1B). Cav-1 expression was also 
tested on a tissue microarray of 110 patients with pancreatic cancer, and scored semi-quantitatively for 
low versus high expression. While Cav-1 is virtually absent in pancreatic ductal or acinar epithelial cells 
from which these tumors are derived (intensity score 0), 100% of 106 tumors with available staining data 
had some degree of Cav-1 staining: in the carcinoma cells, 60% were scored as weak (intensity score 1), 
34% intermediate (intensity score 2), and 6% strong (intensity score 3) (Fig. 1B, right). Given the high 
preponderance of KRAS activating mutations in PC (~90%), we hypothesized whether KRAS mutations 
could be contributing to the high frequency of Cav-1 expression in pancreatic cancer. In order to address 
this, we utilized 2 independent isogenic cell line pairs (SW48 and DLD-1 cells), that were completely 
matched albeit due the presence of one mutated KRAS allele. Interestingly, the presence of a single 
mutated KRAS allele increased Cav-1 expression in these isogenic cell lines, perhaps accounting for the 
high frequency of Cav-1 up-regulation in PC (Supplemental Fig. S1). Taken together, while the majority 
of pancreatic cancers up-regulate Cav-1, the degree of this up-regulation varies between tumors.
Next, we correlated Cav-1 expression (dichotomized by low versus high scores) in the tissue microar-
ray with clinical characteristics such as tumor histopathologic grade, serum CA19-9, and clinical out-
comes including relapse-free survival (RFS), disease-free survival (DFS), and overall survival (OS). Higher 
Cav-1 expression was significantly associated with higher pre-operative CA 19-9 levels (a known poor 
prognostic marker in pancreatic cancer) by Pearson correlation statistical analysis (r = 0.235, p = 0.04; 
n = 74). In addition, higher tumor grade was significantly associated with increasing Cav-1 Allred score, 
indicating that Cav-1 is significantly up-regulated in more poorly differentiated tumors (Fig. 1C). Most 
importantly, higher Cav-1 expression is significantly correlated with worse clinical outcomes, such as 
worse relapse-free survival (p = 0.01), worse disease-free survival (p = 0.03), and a trend for worse over-
all survival (p = 0.13) (Fig. 1D).
Cav-1 Downregulation Results in Decreased Proliferation, Invasion and Migration. Given 
the finding that Cav-1 is overexpressed in pancreatic cancer and is associated with worse outcomes, we 
determined whether or not caveolae could have a role in promoting pancreatic cancer tumor cell survival 
and proliferation. First, we disrupted caveolae with the cholesterol chelator methyl-beta-cyclodextran 
(Mβ CD), and performed WST-1 proliferation assays in multiple pancreatic cancer cell lines. Treatment 
with Mβ CD disrupted cell proliferation in all three cell lines, suggesting that caveolae have a role in PC 
cell proliferation (Fig. 2A). Since Mβ CD also disrupts other types of lipid rafts, we more directly assessed 
the role of Cav-1 in PC cell proliferation, by transfecting multiple PC cell lines with two distinct siRNA 
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pools targeted against different conserved regions of Cav-1. Genetic downregulation of Cav-1 via siRNA 
resulted in reductions in cell proliferation and colony formation using multiple pooled Cav-1 siRNAs, 
compared with scrambled control siRNA, indicating that Cav-1 has specific roles in tumor cell prolifera-
tion (Fig. 2B). To further investigate this finding, cell cycle analysis was performed to determine whether 
loss of Cav-1 alters cell cycle distribution, but no substantial differences in cell cycle assortment were 
noted (Supplemental Table S1).
To evaluate the role for Cav-1 in PC cell invasion, we depleted Cav-1 from cells with siRNA or shRNA 
and performed Transwell invasion assays and wound healing (scratch) assays to evaluate the role of 
Cav-1 in these important tumor cell functions. Similar to previous reports, invasion and migration were 
decreased in response to Cav-1 down-regulation (Fig. 2C, D)8. These results indicate that Cav-1 supports 
pro-tumorigenic functions in PC cells including proliferation, invasion, and migration.
Cav-1 is Up-Regulated After Genotoxic Chemotherapy or Ionizing Radiation, and Cav-1 Loss 
Sensitizes Cells to Genotoxic Therapy with Increased Activation of Apoptotic Response 
Pathways. In addition to surgical resection, two other therapies for PC include chemotherapy and 
Figure 1. Cav-1 expression is up-regulated in pancreatic cancer and is associated with increased tumor 
grade and worse clinical outcomes. A. Western blot images showing expression of Cav-1 in normal and 
PC cells with GAPDH as a loading control. B. Left -Immunohistochemistry (IHC) staining of normal 
human pancreatic tissue (n = 4), xenograft tumor tissues derived from MIAPaCa-2 cells (n = 2), human 
patient-derived xenografts (n = 3), and tumors from KPC transgenic mice (n = 3), showing increased Cav-1 
staining in pancreatic cancer compared to normal pancreatic tissue (inset at greater magnification). Right - 
Representative Cav-1 IHC staining of cores from a tissue microarray showing weak, intermediate, and strong 
intensity, with intensity scores of 1, 2, and 3 respectively. C. Mean Cav-1 IHC Allred score based on degree 
of tumor differentiation (well, moderate, poor). D. Low Cav-1 expression (Allred score 0-4) is significantly 
associated with improved RFS and DFS, with a trend towards improved OS, compared to high Cav-1 
expression (Allred score 5-8).
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radiation. Gemcitabine and 5-fluorouracil (5-FU) are two common chemotherapeutic agents widely 
used in PC with or without radiation. In order to assess a potential role for Cav-1 in therapy response, 
we first tested whether therapeutic stress with chemotherapy or ionizing radiation could alter levels of 
Cav-1 within PC cells. We found that commonly used chemotherapeutics used to treat pancreatic can-
cer increased Cav-1 expression (Fig. 3A). Similar to previous reports13,14, radiation also increases Cav-1 
expression in a time-dependent manner in PC cells (Fig. 3B).
Since Cav-1 is upregulated in PC cell lines after treatment with chemotherapeutics we hypothesized 
that Cav-1 could serve to protect PC cells from these therapies. Indeed, loss of Cav-1 sensitized multiple 
Figure 2. Cav-1 is essential for proliferation, invasion, and migration of pancreatic cancer cells. A.  
Pre-treatment of MIAPaCa-2, Panc-1 and BxPC3 cell lines with methyl-β -cyclodextran (Mβ CD) at 5 mM for 
1 hour results in reductions in proliferation as measured by WST-1 assay (48 hrs). Absorbance is plotted on 
the y-axis where readings at 450 nm are subtracted from background reading at 600 nm, (*p < 0.05; n = 3). 
B. WST-1 assay comparing treatment with scrambled siRNA (“control”) and Cav-1 siRNA (“siCav-1”) in 
MIAPaCa-2 cells (top panel). Colony forming assays after treatment with scrambled control siRNA or Cav-1 
siRNA on MIAPaCa-2 and BxPC3 cell lines (p < 0.05, n = 3, bottom panels). Western blot (top left) confirms 
appropriate Cav-1 depletion with Cav-1 siRNA in both cell lines. Virtually identical results were observed 
with a completely distinct set of pooled siRNA to Cav-1 (data not shown). C. Cells were seeded in 1% FBS-
containing medium into the tops of Transwell chambers coated with Matrigel and incubated for 24 hours 
before being washed and fixed. Chemoattractant in the bottom well was 10% FBS. Columns represent 
percentage of invasion relative to control siRNA for different cell lines pre-treated with scrambled siRNA 
(control) and siCav-1 siRNA pools for 48 hours (left panel, p < 0.05, n = 4). D. Scratch (wound-healing) 
assay to measure migration, showing the percentage wound area plotted against time for scrambled siRNA 
(control)and siCav-1 treated MIA PaCa-2 cells (right panel). Note that control cells show almost complete 
closure of the “wound” compared to Cav-1 knockdown cells by 48 hours, suggesting a migration defect in 
Cav-1 depleted cells (*p < 0.05; n = 3).
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PC cell lines to both gemcitabine and 5-FU (Fig. 4A). These results were corroborated in colony forming 
assays (Fig. 4B). Treatment with even lower doses of 5-FU in the nanomolar range also resulted in atten-
uated proliferation in both cell lines where Cav-1 was transiently knocked down as compared to cells 
treated with scrambled control siRNA. (Supplementary Fig. S2). In order to determine whether loss of 
Cav-1 was affecting apoptotic signaling in response to chemotherapy, we investigated activation of apop-
totic signaling pathways. After Cav-1 downregulation, treatment with gemcitabine led to increased levels 
of cleaved caspase-9, a key component of the intrinsic apoptotic pathway, and cleaved PARP (Fig. 4C). 
Akt activation was also reduced in response to Cav-1 depletion and was maximally reduced in response 
to the combination of Cav-1 siRNA and gemcitabine treatment, suggesting that Cav-1 may promote 
survival to chemotherapeutics in part through Akt activation. Together, these results suggest Cav-1 is 
important in promoting tumor resistance to chemotherapeutics in PC cells and that targeted Cav-1 
knockdown sensitizes PC cells to genotoxic agents such as gemcitabine and 5-fluorouracil through acti-
vation of apoptosis and inactivation of pro-survival signals.
Cav-1 Loss Sensitizes Cells to Ionizing Radiation, with Alterations in DNA Damage 
Response. As shown in Fig.  3B, Cav-1 levels were markedly upregulated in a time-dependent 
Figure 3. Cav-1 expression increases in response to chemotherapeutics and radiation. Immunoblotting 
for Cav-1 expression in MIAPaCa-2 and BxPC3 cell lines at various time points after treatment with  
(A) 50 nM gemcitabine or 20 μ M 5-FU, or (B) after radiating with 2Gy, 4Gy or 6Gy. β -actin was used as a 
loading control.
www.nature.com/scientificreports/
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fashion, suggesting a role for Cav-1 in radiation response. Similar to previous published results13, we 
also found that Cav-1 down-regulation with siRNA sensitizes PC cells to radiation (Supplemental 
Fig. S3). Furthermore, Cav-1 depletion significantly increased the fraction of cells undergoing mitotic 
catastrophe after radiation as indicated by the presence of abnormal multi-lobulated nuclei, suggesting 
a role for Cav-1 in DNA damage response and/or repair (Fig.  5A). Likewise, Cav-1 down-regulation 
also resulted in delayed resolution of gamma H2A.X nuclear foci (phospho-H2A.X Ser139), most pro-
nounced at 24 hrs after radiation (Fig. 5B). Together, these two findings suggest that Cav-1 loss results 
in deficiencies in DNA damage response or repair. In order to further investigate this, we assessed two 
major mechanisms of DNA double strand break repair after radiation: homologous recombination (HR) 
and non-homologous end joining (NHEJ)18–21. Given that BRCA1 is an important intermediary in HR 
repair22, we assessed BRCA1 focus formation. We observed a marked decrease in BRCA1 nuclear foci 
in Cav-1 knockdown cells after radiation (Fig. 5C, top). Since DNA-PK is an important component of 
NHEJ repair, we also assessed phosphorylated DNA-PK (S2056) focus formation after radiation. Similar 
to BRCA1, Cav-1 depletion resulted in a significant reduction in phosphorylated DNA-PK nuclear foci 
after radiation through most timepoints (Fig.  5C, bottom). In corroboration of these findings, Cav-1 
Figure 4. Cav-1 confers resistance to chemotherapeutics and Cav-1 knockdown leads to increased 
chemosensitivity. A. WST-1 assays showing cell proliferation with percentage absorbance of siCav-1 treated 
cells normalized to scrambled control siRNA with gemcitabine (50 nM) and 5-FU (20 μ M) in MIAPaCa-2 
cells (top panels) and BxPC3 cells (bottom panels). B. Colony forming assays with scrambled control 
siRNA or Cav-1 siRNA.Y-axis shows percentage of colony forming units (1 CFU = > 50 cells) normalized 
to controls with gemcitabine (25 nM for MIAPaCa-2 and 50 nM for BxPC3) and 5-FU (20 μ M) treatment 
on MIAPaCa-2 (top panels) and BxPC3 (bottom panels) cells. The lower concentration of gemcitabine was 
required for MIAPaCa-2 cells compared with WST-1 assay since too few colonies were noted at 50 nM. 
Treating with siCav-1 and chemotherapy resulted in decreased cell viability in both WST-1 and colony 
forming assays (*p < 0.05). C. Immunoblotting showing expression of cleaved caspase 9, cleaved PARP and 
pAkt in scrambled control siRNA and siCav-1 treated MIAPaCA-2 and BxPC3 cell lines treated with or 
without gemcitabine (50 nM).
www.nature.com/scientificreports/
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loss results in decreased phosphorylated BRCA1 and DNA-PK by immunoblotting, particularly at 24 
hrs after radiation (Fig. 5D, top). While defects in both HR and NHEJ signaling repair were noted after 
Cav-1 down-regulation, no significant changes in early activation of DNA damage response were found 
as measured by phospho-ATM S1981 (data not shown). Furthermore, Cav-1 siRNA induced higher lev-
els of apoptosis pathway activation 24 hours after radiation (Fig. 5D, bottom). As mentioned previously, 
we did not detect any differences in cell cycle distribution with Cav-1 loss with or without radiation 
(Supplemental Table S1), indicating that changes in cell cycle distribution could not account for the 
Figure 5. Cav-1 knockdown sensitizes tumor cells to radiation by increasing mitotic catastrophe and 
attenuating DNA damage response signaling A. Quantification of the percentage of cells with mitotic 
catastrophe after 3 Gy radiation (left panels, *p < 0.05). Representative immunofluorescence images of 
presence or absence of mitotic catastrophe at 72 hours in scrambled control and siCav-1 cells (right panels). 
B. Quantification of average number of nuclear pH2A.X foci per cell at multiple time points (*p < 0.05). 
Representative immunofluorescence staining for pH2A.X foci after 3 Gy radiation at 24 hours in scrambled 
control siRNA and siCav-1 cells (right panels). C. Top - Quantification of average number of nuclear BRCA1 
foci per cell at multiple time points (left; *p < 0.05). Representative immunofluorescence staining of BRCA1 
foci after radiation at 24 hrs in scrambled control siRNA vs siCav-1 (right panels). Bottom - Quantification 
of average number of nuclear pDNA-PK foci per cell (left; *p < 0.05). Representative immunofluorescence 
staining of pDNA-PK foci after radiation at 24 hrs in scrambled control siRNA-and siCav-1 (right panels).  
D. Immunoblotting of scrambled control and siCav-1 treated cells with or without radiation at different time 
points for expression of phosphorylated BRCA1, total BRCA1, phosphorylated DNAPK, total DNAPK, and 
beta actin as control (top panel). Note the reductions in phospho-BRCA1 and phospho-DNA-PK at 24 hrs 
after radiation with Cav-1 depletion. Loss of Cav-1 also increases the degree of radiation-induced activation 
of apoptotic signaling at 24 hours after 3Gy (bottom panel). For nuclear foci and mitotic catastrophe 
experiments, at least 50 cells were counted per datapoint.
www.nature.com/scientificreports/
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differences observed: as expected, radiation induced a G2/M arrest, but loss of Cav-1 did not impart 
significant changes in the cell cycle assortment.
Knockdown of Cav-1 Attenuates Tumor Growth in Mice. Given our in vitro and human clinical 
outcomes data, we tested the role for Cav-1 in PC tumor initiation and proliferation in vivo, by injecting 
two different PC cell lines (MIAPaCa-2 and BxPC3) with stable Cav-1 knockdown using two independ-
ent shRNA constructs targeting Cav-1 (shCav-1-A in MIAPaCa-2, and shCav-1-B in BxPC3). Tumor 
initiation was markedly decreased in Cav-1 knockdown cells, with only 8 of 30 (27%) injected mice 
developing tumors, compared to 18 of 30 (60%) injected mice with control cells (p < 0.05, Fisher’s exact 
test). Tumor growth rates were also severely attenuated in mice bearing MIAPaCa-2 shCav-1-A xeno-
grafts compared to control (non-specific) shRNA xenografts (Fig. 6A,B). In order to determine whether 
differences in tumor initiation were related to the athymic model or incomplete immune suppression, 
we also injected NOD SCID and CB17 mice with control and shCav-1 MIAPaCa2 cells (n = 5 tumors 
per cell line). In confirmation of the athymic data, Cav-1 depletion resulted in 0/5 (0%) and 1/5 (20%) 
Figure 6. Cav-1 is essential for tumor growth and proliferation in vivo. Tumor growth curves for  
(A) MIAPaCa-2 shCav-1-A bearing and (C) BxPC3 shCav-1-B bearing xenografts in athymic nude mice 
measured by tumor volumes up to 30 days after injection of cells. Growth curves for xenografts resulting 
from scrambled control shRNA (“control”) cells for each cell line are also shown for comparison. Bar graph 
shows mean number of days for tumors to reach 150 mm3 for MIAPaCa-2-shCav-1-A (B) and BxPC3-
shCav-1-B (D) xenografts. Insets in (A) and (C) are immunoblotting confirming Cav-1 down-regulation in 
the stable cell lines. Inset in (B) is a representative image demonstrating the difference in size of scrambled 
control shRNA versus MIAPaCa-2-shCav-1–A tumors at about 30 days after injection. For each cell line, at 
least n = 5 mice per study group were used; *p < 0.05.
www.nature.com/scientificreports/
9Scientific RepoRts | 5:10867 | DOi: 10.1038/srep10867
NOD-SCID and CB17 mice developing tumors, respectively, compared to 4/5 (80%) and 5/5 (100%) con-
trol mice (p < 0.05, Fisher’s exact test). With BxPC3 xenografts harboring a completely distinct shRNA 
(shCav-1-B) compared to the MIAPaCa-2 xenografts, there was likewise a substantial attenuation in 
growth rate (Fig. 6C,D). Due to the substantial effects of Cav-1 loss on tumor initiation and growth rate, 
we were unable to independently assess the effects of Cav-1 levels on chemotherapy or radiation response 
using these cell line models. Taken together, these results indicate that Cav-1 is essential for growth and 
progression of PC cells in vivo as well as in vitro.
Knockdown of Caveolin-1 inhibits STAT3, Src, and JNK signaling in pancreatic tumor cells. In 
order to better define a mechanism for how Cav-1 loss attenuates tumor cell growth, we performed 
comprehensive immunoblotting of various signaling pathways in our isogenically matched MIA-PaCa2 
and BxPC3 cells. In doing so, we identified alterations in the JAK-STAT signaling pathway. Specifically, 
loss of Cav-1 leads to increased levels of SOCS2 (suppressor of cytokine signaling), a negative regula-
tor of JAK-STAT signaling (Fig.  7A). Concordant with our finding, Cav-1 depletion leads to reduced 
Figure 7. Knockdown of Caveolin-1 leads to decreased STAT3, Src and proliferative signaling in vitro. 
(A) shCav-1 downregulated cells in both MIAPaCa-2 and BxPC3 cell lines showed decreased phosphoJAK2 
at residues Tyr1007/1008 and phosphoSTAT3 at Tyr705 as compared to scrambled control shRNA cells. 
Total levels of JAK2 and STAT3 are unchanged. SOCS2 and PIAS3, both inhibitors of the JAK-STAT 
pathway, are upregulated in Cav-1 knockdown cells. Phosphorylation of Src at Tyr416, the activation site, is 
decreased while phosphorylation of Src at Tyr 527, the inhibition site, is increased. GAPDH equal loading 
control remains unchanged. (B) Phosphorylation of JNK at Thr183/Tyr185, p38MAPK at Thr180/Tyr182 
and pERK1/2 at Thr202/Tyr204 is decreased in both cell lines with knockdown of Cav-1, consistent with 
global reduction in proliferative pathways. Totals remain unaffected. DUSP5 levels are increased in both cell 
lines concomitantly. GAPDH shows equal loading control. (C) Schematic depicting the pathways affected in 
signaling when Cav-1 is downregulated in pancreatic cancer cell lines.
www.nature.com/scientificreports/
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activation of JAK2 and downstream STAT3 signaling (Fig.  7A). Furthermore, loss of Cav-1 was asso-
ciated with increased PIAS3 (protein inhibitor of activated STAT3) levels, a protein which negatively 
regulates STAT3. Since the JAK-STAT pathway is an important regulator of cell survival and cytokine 
receptor signaling, our data suggests that knocking down caveolin-1 affects cell survival and proliferation 
in pancreatic cancer cells via this pathway. In addition, we identified that loss of Cav-1 led to decreased 
activation of the JNK/SAPK pathway, as well as p38 and p42/44 MAPK signaling, suggesting probable 
suppression of survival pathways. (Fig.7B).This may also explain the proliferation defect that we found 
initially when Cav-1 was knocked down (Fig. 2B). Concomitant with this finding, we found that Cav-1 
depletion increased DUSP5 levels, a nuclear protein which negatively regulates JNK as well as p38 and 
ERK1/223–25. Lastly, since Cav-1 was first identified as a substrate of v-Src, we queried whether loss of 
Cav-1 altered endogenous c-Src activation. We found that Cav-1 knockdown resulted in attenuation of 
Src signaling as observed by decreased Y416 phosphorylated Src (activated form), and increased Y527 
phosphorylated Src (inhibited form) (Fig.  7A). Since JAK2, SOCS, JNK/SAPK, and Src signaling all 
converge and impinge on STAT3 signaling, our data suggests that loss of Cav-1 serves to reduce pancre-
atic cancer oncogenic proliferation, migration, invasion, and cell survival through a STAT3 mechanism 
(Fig. 7C).
Discussion
Here, we have performed a comprehensive study elucidating diverse roles for Cav-1 in PC. Using human 
samples, we demonstrate that Cav-1 is a prognostic biomarker in pancreatic cancer. Our results also 
indicate that Cav-1 is essential for growth, invasion, and proliferation of PC cells both in vitro and in 
vivo. We also demonstrate that Cav-1 potentiates resistance to radiation and chemotherapeutics such as 
gemcitabine and 5-FU, suggesting that targeting this pathway may lead to improved therapeutic response. 
Finally, we establish a novel role for Cav-1 in a SOCS-JAK-STAT-SRC signaling pathway in pancreatic 
cancer cells.
Previously, Cav-1 expression has been correlated with increased tumor diameter, poor histopathologic 
grade, and poor prognosis in a clinical cohort of 79 Japanese PC patients. Interestingly, this study also 
demonstrated that expression of Cav-1 was not elevated in chronic pancreatitis, thus providing more 
data for Cav-1 as a suitable potential biomarker for invasive pancreatic carcinoma26. Another clinical 
study of fewer patients also found fatty-acid synthase (FAS) and Cav-1 are co-expressed in PC and are 
associated with poor survival, providing further evidence for Cav-1 as a potential PC biomarker27. Our 
data from a significantly larger clinical dataset similarly demonstrates Cav-1 to be associated with worse 
tumor histologic grade and clinical outcomes.
Prior reports have linked Cav-1 overexpression with oncogenic transformation, invasion, and metas-
tasis8,28–30. We similarly found that Cav-1 knockdown by multiple distinct siRNAs reduced prolifera-
tive, invasive and migratory properties of PC cells in multiple cell lines. Disruption of lipid rafts by 
Mβ CD also led to a decrease in proliferation, suggesting intact lipid rafts and caveolae are essential for 
Cav-1 signaling. This change in rate of proliferation was not due to changes in the cell cycle as shown 
in Supplemental Table S1. Most importantly, our in vitro results were corroborated in vivo, as Cav-1 
down-regulation markedly attenuated tumor initiation and growth rates in mice, providing direct evi-
dence that Cav-1 is essential for tumorigenicity, growth and proliferation in pancreatic cancer. To our 
knowledge, the findings of such direct effects of Cav-1 on tumor initiation, growth and proliferation in 
pancreatic cancer cells is a novel finding.
Treatment by gemcitabine and 5-fluorouracil (5-FU), are two common chemotherapeutic approaches 
for PC. We found that increasing length of chemotherapy exposure increased Cav-1 expression perhaps 
in a “stress-like” response, and that Cav-1 depletion led to increased sensitivity to both chemotherapeu-
tics, particularly gemcitabine. Activation of the intrinsic pathway of apoptosis is a common mode of 
tumor cell death under conditions of chemotherapeutic stress and involves activation of caspases like 
cleaved caspase 931–33. Our results also indicate that Cav-1 knockdown sensitizes PC cells to chemother-
apy through the intrinsic pathway of apoptotic cell death, with concomitant loss of Akt pro-survival 
signals. To our knowledge, a role for Cav-1 in promoting chemoresistance through protection from 
activation of the intrinsic pathway of apoptosis is a novel finding.
Similar to chemotherapeutics, radiation is commonly used in PC34–37. We have found that Cav-1 
expression increased with time in multiple PC cell lines after radiation, similar to a previous report13. After 
radiation, phosphorylated H2A.X is recruited to sites of double strand DNA breaks, and itself recruits 
proteins to effect DNA repair38,39. We have extended our results to show that Cav-1 down-regulation 
leads to delayed repair of radiation-induced DNA damage, as demonstrated by delayed pH2A.X foci 
resolution. Delayed resolution of these foci suggests inhibition of repair, leading to accumulation of 
damaged DNA and an inability to properly divide following replication40–43. In confirmation of this, 
we observed an increased number of multi-nucleated cells indicating increased mitotic catastrophe in 
Cav-1 depleted cells after radiation, with subsequent clonogenic radiosensitization. Mechanistically, we 
observed that knocking down Cav-1 affected both HR and NHEJ processes of double strand break repair, 
similar to a previous report21. Radiation-induced Cav-1 has also been shown to be involved in nuclear 
translocation of EGFR with subsequent activation of DNA-PK, which may provide one possible mecha-
nism for a role for Cav-1 in double strand break repair44. We have also provided novel data implicating 
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Cav-1 in facilitating BRCA1 and DNA-PK mediated DNA repair and protection from intrinsic apoptosis 
after ionizing radiation.
Finally, our data suggests that Cav-1 depletion in pancreatic cancer cells affects various pathways, 
particularly the JAK/STAT pathway, by decreasing activation of JAK2 and STAT3 and by increasing 
SOCS2, PIAS3, and DUSP5 inhibitory signals. JNK has been another proliferation pathway involved in 
stress-induced proliferation and survival, but which has also been shown to promote STAT3 activation45. 
We find that loss of Cav-1 reduces JNK activation, perhaps through increased function of the JNK inhib-
itor DUSP5. In addition, Src and Src family tyrosine kinases are well-characterized caveolae-associated 
proteins, which have been shown to bind Cav-1,phosphorylate Cav-1, and be regulated by Cav-128,46,47. 
Our data indicates that Cav-1 depletion results in reduced Src activity, providing further evidence that 
Cav-1 has pro-tumorigenic functions, perhaps through a direct association between Cav-1/caveolae and 
Src. Furthermore, Src has been shown to promote STAT3 activation and JNK48,49,50. Also, STAT3 has 
been shown to bind to the promoter region of Cav-1 in breast cancer51 and may thus result in a positive 
feedback loop if the same phenomenon occurs in pancreatic carcinoma. Thus, many signals in the Cav-1 
signaling pathway appear to be converging on the STAT3 pathway. STAT3 is a well-characterized positive 
regulator of various cell survival and signaling pathways, through activation of transcriptional programs 
leading to tumor cell proliferation, survival, migration/invasion, metastasis, immune evasion, and tumor 
angiogenesis52. Overall, our data establishes a novel interaction between Cav-1 and both JAK/STAT3 and 
JNK signaling in tumor cells, and we postulate that Cav-1 and caveolae directly promotes activation of 
STAT3 and JNK pathway activation through Src. Future efforts will be directed at further clarification 
of this pathway.
In summary, our data demonstrate a pro-tumorigenic role for Cav-1 in PC cell proliferation, tumor 
initiation, tumor growth, invasion, migration and multimodality therapeutic resistance. Our studies also 
demonstrate a novel role for Cav-1 in promoting JAK/STAT and JNK activation in tumor cells. Further 
studies are required to better elucidate the signaling pathways downstream of Cav-1 involved in these 
processes and identify novel ways to directly or indirectly target the Cav-1/caveolae pathway in PC for 
therapeutic efficacy. Finally, prospective evaluation of Cav-1 as a prognostic and predictive biomarker 
in PC is warranted.
Materials and Methods
Antibodies, Chemicals, and Cell Culture. Anti-caveolin-1 (N-20) and DUSP5 antibody were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti- cleaved caspase-9, cleaved PARP, 
phospho-Akt, total Akt, phospho-BRCA1, phospho-DNAPK, total BRCA1, total DNAPK, phospho-JAK2, 
total JAK2, phospho-STAT3, total STAT3, PIAS3, Src (Y416), Src (Y527), total Src, SOCS2, phospho-JNK, 
total JNK, phospho-p38, total p38, phospho-ERK1/2, total ERK1/2, alpha tubulin, phospho-H2.AX, 
beta actin and GAPDH antibodies were purchased from Cell Signaling Technology (Danvers, MA). 
Gemcitabine and 5-fluorouracil (5-FU) was purchased from Sigma-Aldrich (St. Louis, MO) and Santa 
Cruz Biotechnology (Dallas, TX) respectively. For in vitro studies, gemcitabine and 5-FU were dissolved 
in DMSO. MIAPaCa-2, BxPC3, Panc-1, AsPC1, Capan-1, Capan-2, HPAFII and HEK-293 were obtained 
from and authenticated (via short tandem repeat profiling) by the American Type Culture Collection 
(Manassas, VA), and grown according to ATCC recommendations. HPDE cells were kindly provided 
by Dr Diane Simeone (University of Michigan). Cells used for this study were cryopreserved within 
6 months of authentication. SW-48 and DLD-1 isogenic cell line pairs were obtained from Horizon 
Discovery (Cambridge, UK). Cells were passaged for no longer than 3 months and grown in a 37 °C 
incubator with 5% CO2.
Caveolin-1 knockdown. Scrambled nonspecific control and anti-Cav-1 SMARTpool siRNA were 
purchased from Dharmacon (Lafayette, CO). A second set of siRNA targeting Cav-1 was purchased from 
SantaCruz Biotech (Dallas, TX). Transfections were performed according to manufacturer’s protocol 
using Oligofectamine (Invitrogen). Transient transfections were carried out 48 hours before drug treat-
ment or radiation. For stable Cav-1 knockdown, cells were transduced with shRNA lentiviral particles 
(SantaCruz Biotech) and stable pools were selected with puromycin.
Immunoblotting. Immunoblotting was performed as described before53. Briefly, cell lysates were pre-
pared in RIPA lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCL pH 7.4, 0.25% Na-deoxycholate, 
1 mM EDTA) supplemented with 1x protease inhibitor (Complete, Roche Applied Science) and phos-
phatase inhibitors (PhosSTOP, Roche Applied Science). Protein concentration was determined with a 
Dc Protein Assay Kit (BioRad, Hercules, CA). Proteins were resolved by SDS/PAGE and transferred 
to nitrocellulose membranes. Primary antibodies were allowed to bind overnight at 4℃, and used at 
a dilution of 1:500-1,000. After washing in TBS-Tween, membranes were incubated with horserad-
ish peroxidase-conjugated secondary antibodies diluted 1:2,500 for 1 hour. Membranes were washed 
with TBS-Tween and incubated for 1 minute with enhanced chemiluminescence reagent (Amersham 
Pharmacia, Uppsala, Sweden) prior to film exposure.
Cell Proliferation Assays. Cells were plated in 96 well format and treated with DMSO, gemcitabine 
or 5-FU for 48 hours before the assay. Cell proliferation assay was performed with WST-1 reagent (Roche) 
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according to their protocol. Briefly, 10 μ l of WST-1 reagent was added to each well after treatment and 
incubated at 37 °C for four hours. Absorbance was read at two wavelengths, 450 nm and 600 nm for 
endpoint absorbance and background absorbance, respectively. The absorbance difference was plotted 
on the y-axis with the treatment conditions on x-axis.
Colony Forming Assays. Cells were trypsinized to generate single cell suspensions and seeded into 
60 mm tissue culture plates in triplicate. Cells were incubated with DMSO or gemcitabine or 5-FU for 
a total of 24 hours before changing the medium. If irradiated, cells had medium changed 24 hours after 
radiation. At 7-14 days after seeding, colonies were stained with 0.5% crystal violet, and the numbers 
of colonies or colony forming units (CFU) containing at least 50 cells were counted. Experiments were 
repeated multiple, independent times.
Experimental Radiation. Irradiation was performed essentially as described previously with 160 kV, 
25 mA at a dose rate of approximately 113cGy/min using a RS-2000 biological irradiator (RadSource,GA)53.
Immunofluorescence. Cells were plated on coverslips and treated with chemotherapeutics or radi-
ation, then fixed with 2% paraformaldehyde for 15 minutes at room temperature, rinsed with PBS and 
permeabilized with 1% Triton-x-100 for 10 min on ice. After rinsing, cells were blocked with 3% bovine 
serum albumin for 1 hour or overnight at 4 °C. In a humidified chamber, primary antibodies were added 
in blocking solution and incubated for various times, rinsed, and secondary antibody was added along 
with DAPI for 1 hour at room temperature. Cells were then rinsed, mounted with coverslips, and sealed 
until visualization with a confocal microscope.
Flow cytometry. Flow cytometry was performed as described previously53. Briefly, cells were plated 
in 6 well dishes, and treated with or without radiation. At 24 hours following radiation exposure, cells 
were harvested with trypsin, washed with medium, centrifuged, and resuspended in 1 mL PBS. Cells 
were immediately fixed for 30 minutes with 9 ml ice-cold 80% ethanol added slowly with mixing. Cells 
were washed twice with PBS and resuspended in 1 mL PBS containing 10 μ g/mL propidium iodide and 
0.25 mg/mL RNase A. Cells were incubated for 30 minutes and stored in the dark prior to analysis. Cells 
were then transferred to 5 mL polystyrene round bottom tubes through cell strainer lids and analyzed on 
a FACS Calibur (BD Biosciences). Data was fit using ModFit LT (Verity Software House).
Immunohistochemistry. Immunohistochemistry was performed as described before53. Briefly, slides 
were deparaffinized in xylene (3 changes of 2 minutes each) and then rehydrated through graduated 
alcohols of 2 minutes each (100%, 95%, and 70%) followed by distilled water. The slides were placed 
in a 3% peroxidase block for 5 minutes, followed by antigen retrieval for 25 minutes in pH 6.0 citrate 
buffer in a microwave, cooled and washed in distilled water. After rinsing in TBS, slides were incubated 
with a primary antibody for caveolin-1 (N-20, SantaCruz) at 1:200 for 60 minutes on a Biocare Medical 
Intellipath Autostainer. After primary antibody incubation, the slides were rinsed and incubated with a 
horseradish perodixase (HRP) Polymer two-step system with a conjugated rabbit secondary antibody for 
20 minutes (Dako). Slides were rinsed again in TBS, incubated with DAB + (Dako) for 5 minutes, then 
rinsed and counterstained with hematoxylin for 10 seconds. Slides were then rinsed in ammonia water 
and dehydrated in graduate alcohols following the opposite order (70%, 95% and 100% alcohol) followed 
by xylene, and mounting with a coverslip.
Animal experiments. In vivo experiments were conducted as described previously53. Six to eight 
week-old male nude mice (Taconic Farms Inc., NY) were caged in groups of five or less, and fed a diet 
of animal chow and water ad libitum. MIAPaCa-2 and BxPC3 stable cell lines bearing control or Cav-1 
shRNA (2–4 × 106 cells each) were injected subcutaneously into the flanks of each mouse. To obtain a 
tumor growth curve, perpendicular diameter measurements of each tumor were measured every 3 days 
with digital calipers, and volumes were calculated using the formula (L × W × W)/2. Animal studies were 
conducted in accordance with an approved protocol adhering to the IACUC policies and procedures at 
The Ohio State University.
Tissue Microarray. A tissue microarray was created from 110 patients treated with surgery and 
chemoradiation for pancreatic cancer at the University of Michigan. All tissue cores were obtained 
from diagnostic or surgical samples, and the most representative, non-necrotic areas were chosen by an 
experienced pathologist (D.T.). All hematoxylin and eosin stained slides of the tumors were reviewed, 
and tissue microarrays were constructed as described previously54. Tissue cores (1.0 mm in diameter) 
were taken from spatially separate areas in a single donor block from each case using a tissue microar-
rayer (Chemicon Advanced Tissue Arrayer, Temecula, CA). Cores were arrayed into a recipient block 
at predetermined coordinates (2 cores per patient). The H&E stained sections from donor and recipient 
paraffin blocks were used to confirm the area of tumor from which cores were retrieved. After immu-
nohistochemical staining, expression of Cav-1 was scored using the Allred method by an independ-
ent pathologist blinded to patient data (D.T.), by determining the average intensity score (0 = none, 
1 = weak, 2 = intermediate, 3 = strong) and percent cells staining score (0 = none, 1 = < 1%, 2 = 1–10%, 
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3 = 10–33%, 4 = 33–66%, 5 = > 66%), and summing the scores for a range of 0-855. Scores from each of 
the 2 cores were averaged. High and low Cav-1 expression was classified by dichotomizing Allred score 
from 0-4 (low) to 5-8 (high).
Data Analysis. Data are presented as the mean ± standard error of the mean (s.e.m.) for clonogenic 
survival and tumor growth experiments. The group comparisons of the percent change in tumor vol-
ume were performed at individual time points. Statistical comparisons were made between the control 
and experimental conditions using the unpaired two-tailed Student’s t-test with significance assessed at 
p-values < 0.05. Overall survival (OS), relapse-free survival (RFS), disease-free survival (DFS) were deter-
mined using the Kaplan-Meier method. RFS indicates percent of patients free of first relapse (whether 
local, regional, or distant). DFS indicates percent of patients free of any relapse or death. The log-rank 
test was used to determine if Cav-1 expression was associated with outcomes, with p < 0.05 considered 
significant. Patients lost to follow-up were censored. Stata, version 11 (StataCorp, College Station, TX) 
was used to perform the statistical analyses.
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